


Supporting treatment decisions for patients with Alzheimer's disease using explainable artificial intelligence

Norway Life Science 2026, January 12, 2026



Esten H. Leonardsen

Chief Scientific Officer, baba.vision
Post-doctoral research fellow,
Department of Psychology,
University of Oslo



baba vision


New treatment options for Alzheimer's disease




New medications



New treatment options for Alzheimer's disease



Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine*, 388(1), 9-21.





Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., ... & Kaul, S. (2023). Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*, 330(6), 512-527.




New treatment options for Alzheimer's disease




New treatment options for Alzheimer's disease




New treatment options for Alzheimer's disease




New treatment options for Alzheimer's disease



New treatment options for Alzheimer's disease



New treatment options for Alzheimer's disease



Treatment eligibility

Explainable artificial intelligence

The future of Alzheimer's treatment

Thank you for your attention!
esten@baba-vision.com

baba vision

